Accropeutics, Anyea, Myrobalan Therapeutics and ReviR Therapeutics announced that AC‑101, ANY‑108, ANY‑112, MRO‑001HS and RTX‑117 have been admitted into the pilot initiative encouraging the research and development of innovative therapies for rare diseases, marking a coordinated regulatory endorsement of five differentiated programs across autoinflammatory, neurogenetic and neurodegenerative medicine.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Initiative | Pilot program encouraging R&D of innovative therapies for rare diseases |
| Selection Date | 12 Oct 2026 |
| Products Admitted | AC‑101; ANY‑108; ANY‑112; MRO‑001HS; RTX‑117 |
| Sponsors | Accropeutics; Anyea; Myrobalan Therapeutics; ReviR Therapeutics |
| Therapeutic Areas | Autoinflammatory disease, CNS/neurology, ALS, neuromuscular and leukodystrophy disorders |
| Prior Designation | AC‑101 – U.S. FDA Rare Pediatric Disease (RPD) designation (June 2026) |
| Next Steps | Advancement under pilot‑supported development pathways; timelines Not disclosed |
Drug Profiles & Mechanisms of Action
- Accropeutics – AC‑101: A novel, selective RIPK2 inhibitor in development for Blau syndrome (BS), a rare inherited autoinflammatory disorder caused by pathogenic NOD2 gene variants that typically presents in early childhood. BS is characterized by the classic triad of granulomatous dermatitis, arthritis and uveitis; joint inflammation can cause deformities and functional impairment, while ocular inflammation may lead to severe visual loss or blindness. In June 2026, the U.S. FDA granted Rare Pediatric Disease (RPD) designation to AC‑101 for BS.
- Anyea – ANY‑108 / ANY‑112: An R&D‑focused biotechnology enterprise centered on innovative therapies for neurological disorders. Since its inception in September 2022, Anyea has built an end‑to‑end R&D pipeline for innovative brain disease drugs. ANY‑108 targets Angelman syndrome; ANY‑112 targets primary familial brain calcification caused by SLC20A2 haploinsufficiency.
- Myrobalan Therapeutics – MRO‑001HS: A preclinical‑stage biotechnology company headquartered in Medford, Massachusetts, developing oral neurorestorative therapies aimed at reversing key pathologies in brain dysfunction and central nervous system (CNS) diseases. MRO‑001HS is in development for amyotrophic lateral sclerosis (ALS).
- ReviR Therapeutics – RTX‑117: A clinical‑stage global biotechnology company developing therapies across neurology, immunology & inflammation, and oncology. RTX‑117 is a potential first‑in‑class, orally administered small molecule whose discovery and molecular design were supported by XtalPi’s AI and robotics‑driven drug discovery platform. RTX‑117 modulates the integrated stress response (ISR) pathway by activating eIF2B, a critical regulator of protein translation, aiming to restore mRNA translation and protein‑expression homeostasis in ISR‑related diseases.
Development Status at a Glance
| Program | Sponsor | Modality / Target | Lead Indication | Current Stage |
|---|---|---|---|---|
| AC‑101 | Accropeutics | Selective RIPK2 inhibitor | Blau syndrome | FDA RPD designation; clinical stage Not disclosed |
| ANY‑108 | Anyea | Innovative brain disease therapy | Angelman syndrome | Not disclosed |
| ANY‑112 | Anyea | Innovative brain disease therapy | Primary familial brain calcification (SLC20A2) | Not disclosed |
| MRO‑001HS | Myrobalan Therapeutics | Oral neurorestorative therapy | ALS | Preclinical |
| RTX‑117 | ReviR Therapeutics | First‑in‑class oral eIF2B activator (ISR modulation) | CMT and VWM | Phase 1; IND cleared in U.S. and China |
Market Impact & Outlook
- Rare Disease Policy Tailwind: Admission into the pilot initiative signals structured regulatory support for innovative rare disease therapies, a segment historically constrained by small patient populations and limited commercial incentives.
- Neurology‑Centric Cohort: Four of the five admitted programs target CNS or neuromuscular rare diseases – Angelman syndrome, primary familial brain calcification, ALS, and CMT/VWM – underscoring the deep unmet need in neurogenetic and neurodegenerative disorders.
- Mechanistic Diversity: The cohort spans RIPK2‑driven autoinflammation, eIF2B/ISR translation control and oral neurorestoration, offering differentiated approaches rather than me‑too assets.
- AI‑Enabled Discovery: RTX‑117’s backing by XtalPi’s AI and robotics platform highlights the growing convergence of artificial intelligence with rare disease drug design.
- Global Development Footprint: With IND clearance in both the United States and China for CMT and VWM, RTX‑117 is positioned for multi‑regional Phase 1 execution.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory pathways, clinical development timelines and therapeutic potential for AC‑101, ANY‑108, ANY‑112, MRO‑001HS and RTX‑117. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review requirements, and the evolving policies of the pilot initiative.-Fineline Info & Tech
